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Asymptomatic atrial fibrillation (AF) is associated
with similar stroke risk as symptomatic AF, yet is
often detected only after the patient presents with a
devastating stroke. The first Australian guidelines for
the screening and management of AF were released
in 2018 by the National Heart Foundation of
Australia and the Cardiac Society of Australia and
New Zealand. This brief, practical summary of the
guidelines focuses on screening in general practice.

A

trial fibrillation (AF) is a cardiac arrhythmia causing
an uncoordinated contraction of the heart; the atria
do not contract at all, and the ventricular rate is irregular. It is the most common arrhythmia seen by GPs
in Australia, and its incidence is increasing with the ageing
population, rising prevalence of risk factors such as hypertension
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and overweight/obesity, and increased longevity of patients with
cardiac morbidities.1 About 3% of the population, or half a million
adults in Australia, are estimated to have AF, with this proportion
expected to double over the next two decades.2 The prevalence
of AF increases markedly among older adults and is around 10%
in the 75 years and older age group.3
AF is associated with increased mortality, cognitive decline,
dementia, heart failure and renal dysfunction. However, the
most devastating consequence is thromboembolic stroke, and
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KEY POINTS
• Atrial fibrillation (AF) is the most common heart
•
•
•
•

•

arrhythmia, and is associated with a fivefold increased
risk of stroke.
AF increases markedly in prevalence after 65 years of
age and often occurs in patients with multiple
comorbidities.
Opportunistic single-time point AF screening detects
asymptomatic (‘silent’) and largely persistent AF, which
confers similar stroke risk as the symptomatic form.
Australian guidelines recommend opportunistic screening
for AF in all people aged 65 years and older.
Opportunistic screening can be incorporated easily and
with minimal cost in routine patient care in general
practice. New systems and technologies are being
developed to overcome time barriers to screening in
general practice.
Significant reductions in preventable stroke can be
achieved if AF screening works hand in hand with the
provision of treatment and efforts to facilitate patient
adherence.

GPs are in a unique position to detect asymptomatic AF, and
new Australian guidelines recommend that all patients aged
65 years and over should be opportunistically screened for AF
by either pulse palpation or with a handheld ECG rhythm strip.2
If AF is detected then initiation of oral anticoagulant treatment
by GPs can play a central role in reducing stroke risk.
This article provides a brief, practical summary of recent
Australian guidelines on screening for AF, focusing on screening
in general practice.

about one-third of ischaemic strokes are attributed to AF.2,4
These strokes are more likely to be fatal or debilitating and to
have a significant adverse impact on quality of life. Randomised
controlled studies have shown that stroke in patients with AF
can be reduced by two-thirds with oral anticoagulant therapy.5
However, because AF in older people is often asymptomatic
(‘silent’), screening is required to reduce the approximately 10%
of ischaemic strokes related to AF that are first diagnosed at the
time of the stroke.

New national guidelines align with the Australian
primary care environment
Over the past decade, much has changed in the landscape of
AF screening and treatment. In 2015, the Cardiac Society of
Australia and New Zealand (CSANZ) and National Heart
Foundation of Australia (NHFA) undertook a review of emerging cardiovascular issues in Australia, and identified AF as an
increasingly burdensome condition with evolving therapeutic
management options and large treatment gaps.2 In the 2016
revision of the Guidelines for Preventive Activities in General
Practice (Red Book), the RACGP included a new recom
mendation that all patients aged 65 years and older be screened
opportunistically for AF.6 Two years later, the first Australiandeveloped guidelines, Australian Clinical Guidelines for the
Diagnosis and Management of Atrial Fibrillation 2018, were
released by CSANZ and NHFA.2 Key recommendations of these
Australian-specific screening guidelines are summarised in
Box 1.2,6
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Atrial fibrillation screening continued

1. KEY AUSTRALIAN
RECOMMENDATIONS FOR ATRIAL
FIBRILLATION SCREENING2,6
RACGP. Guideline for preventive
activities in general practice (9th ed) 6
Recommendation: Systematic screening
for AF is not recommended; however,
opportunistic screening when
measuring blood pressure or at other
times appears to be cost effective.
NHFA and CSANZ. Australian clinical
guidelines for the diagnosis and
management of atrial fibrillation 20182
Recommendation: Opportunistic
point-of-care screening in the clinic or
community should be conducted in
people aged 65 years or more.
Practice point: Devices that provide a
medical-quality ECG trace are preferred
to pulse-taking or pulse-based devices
for screening, because an ECG is
required to confirm the diagnosis.
Recommendation: Pacemakers and
defibrillators should be interrogated
regularly for atrial high-rate episodes,
which should be confirmed by atrial
ECG to be atrial fibrillation.
Recommendation: For patients with
embolic stroke of unknown source,
longer term ECG monitoring
(external or implantable) should be
used.
Abbreviations: CSANZ = Cardiac Society of Australia
and New Zealand; NHFA = National Heart Foundation
of Australia; RACGP = Royal Australian College of
General Practitioners.

Before these guidelines were developed, AF screening efforts in Australia
were ad hoc, guided by a range of international guidelines with nuanced dif
ferences in recommendations, and not
aligned to the Australian primary care
environment. There are marked differences in primary care between Australia
and other countries that have guided AF
screening, such as Europe, where AF
guidelines recommend opportunistic
screening, and the US, where guidelines
make no recommendation. A distinctive
feature of general practice in Australia
is its model for e quitable provision of
healthcare that is low- or no-cost to
16 MedicineToday

patients.7 Australian GPs tend to be more
engaged in chronic disease management
and are the first port of call for referral
to specialist services. The vast geography
of Australia also dictates that the scope
of primary care provision in rural areas
is often more diverse than in other
countries.
To be effective, screening efforts need
not only to engage the target population
in the screening but also to tackle a significant health issue with an effective
available treatment, to use a screening
method that is low cost and readily available, and also to include a pathway to
access treatments that have demonstrated
benefits in terms of morbidity and
mortality (Box 2).8 AF screening meets
most of these criteria, and Australian
GPs are optimally placed because of their
coverage of the 65 years and over age
group, their preventive health role, and
ability to provide a clear and direct
pathway from the screening of AF to its
management.9

Screening identifies patients
with asymptomatic AF
About two-thirds of patients with AF have
symptoms.2 These patients often present
to their GP or a hospital emergency
department with palpitations or non
specific symptoms such as fatigue, dizziness, dyspnoea or reduced exercise
tolerance. Most will then be investigated
with an ECG, which will detect AF, and
they will be treated accordingly. One-third
of patients with AF are asymptomatic.
The arrhythmia in these patients would
be detected only when discovered incidentally by an ECG performed for another
reason or when the patient presents with
a complication of AF.
In around 10% of patients with stroke
attributed to AF, the AF was asymptomatic, and stroke was the first clinical
presentation.10,11 If the arrhythmia had
been detected earlier and appropriate
treatment commenced, these patients
might have been spared the risk of a
potentially fatal or debilitating outcome.

Stroke is an unacceptable warning sign
for AF. It is crucial to note that asymptomatic AF carries the same stroke risk as
symptomatic AF.12 Screening has the
potential to identify individuals with
asymptomatic AF who are nevertheless
at high risk of stroke, so that stroke prevention treatments can begin in a timely
manner.

Screening for AF is associated
with minimal harms and is
acceptable to patients
The benefits of stroke avoidance outweigh
the minimal risks and theoretical harms
of AF screening.13,14 Screening by pulse
palpation or a single-channel ECG recorded
with a handheld electronic device is not
invasive, carries minimal risk to the
patient and can increase rapport between
practitioners and their patients.15 Patients
positively evaluate the use of novel handheld ECG devices for assessing heart
rhythm.15 Either method of screening is
low cost, fast and easily incorporated into
patient consultations.
Both pulse palpation and ECG recording with a handheld electronic device
have good reliability and validity; however, an irregular pulse always requires
confirmation of AF with either a 12-lead
ECG or an ECG rhythm strip.4 Although
the diagnosis of AF requires only a
30-second ECG rhythm strip, a 12-lead
ECG is required for the additional diagnostic information it provides. The ECG
rhythm strip and 12-lead ECG both need
review by a GP or physician experienced
in ECG interpretation to confirm the
automated diagnosis and reduce the rate
of false positives (which is less than 0.01%
with some automated algorithms for
the detection of AF4), which can lead to
unnecessary investigations, anxiety and
the risks of unnecessary oral anticoagulant therapy.
An important tip is that the handheld
single-channel ECG is actually lead 1
(right arm to left arm) of a multiple-lead
ECG, and the trace is therefore equivalent to the lead 1 trace on a 12-lead ECG.
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Atrial fibrillation screening continued

2. WHO GUIDELINES FOR EFFECTIVE
SCREENING PROGRAMS8
Condition
• The condition should be an important
health problem
• It should have a recognisable latent
or early symptomatic stage
• The natural history of the condition,
including development from latent to
declared disease, should be
adequately understood
Test
• The test should be simple, safe,
precise and validated
• It should be acceptable to the target
population
• The distribution of test values in the
target population should be known
and a suitable cut-off level defined
and agreed
Treatment
• There should be an effective
treatment for patients identified, with
evidence that early treatment leads
to better outcomes
• There should be an agreed policy on
who should be treated and how they
should be treated
Outcomes
• There should be evidence of
improved mortality, morbidity or
quality of life as a result of screening,
and the benefits of screening should
outweigh the harm
• The cost of case finding (including
diagnosis and treatment of patients
who are diagnosed) should be
economically balanced in relation to
possible expenditure on medical care
as a whole
Consumers
• Consumers should be informed of the
evidence so they can make an
informed choice about participation

The finding of P waves in lead 1 of a
12-lead ECG performed after a handheld
ECG rhythm strip showed no P waves
and an irregular rhythm suggests paroxysmal AF, which is occasionally found
through opportunistic single-time point
screening.
18 MedicineToday

Opportunistic point-of-care
screening in the clinic or
community is recommended in
people aged 65 years or more
Many of the formalised screening activities in primary care are systematic screening programs that occur at defined ages
or time intervals. In contrast, opportunistic screening takes place not on a regular
schedule but whenever a patient attends
primary care.6 When screening is incorporated into routine patient care in general
practice, there is a direct pathway for GPs
to review and manage abnormal results.
Further, when screening is undertaken
opportunistically, the repeated screenings
that occur at each patient visit increase
the likelihood of detecting paroxysmal or
new-onset AF.
Opportunistic screening is more likely
to detect persistent or permanent AF,
which is associated with higher stroke
risk, and occasionally detects paroxysmal
AF with a high AF burden. These highburden forms generally develop in ageing
hearts and are also associated with comorbidities such as hypertension, myocardial
ischaemia, diabetes, cardiac failure and
cardiomyopathy.2 Therefore, it is not surprising that the prevalence of known AF
increases with age, with an upswing seen
around 65 years of age and a steady
increase thereafter.16 The prevalence of
asymptomatic AF is more difficult to
ascertain, but recent Australian studies
have estimated a prevalence of 1.4% in the
65 years and over age group, using screening with a single-time point 30-second
handheld ECG in the community and
general practice settings.17,18 When screening is repeated opportunistically as part
of an ongoing program, the cumulative
detection rate is likely to be higher.
General practice is the ideal location
for screening as more than 90% of patients
aged 65 years and over see their GP at
least annually, with 70% visiting at least
twice a year.9 Opportunistic screening
for AF was shown to be cost effective in
an Australian study utilising a single-time
point 30-second handheld ECG in

pharmacies, and opportunistic screening
was shown to be more economical than
systematic screening for increasing quality-adjusted life years and reducing
stroke.17 A limitation of screening in
pharmacies is that it lacks a clear or direct
referral pathway for the management of
patients with results suggesting AF or
other abnormalities.4 The cost effectiveness of screening at GP practices has not
been evaluated in Australia; however, an
economic evaluation is currently underway. Further economic efficiencies would
be expected when opportunistic screening is adopted as an enduring program
rather than a one-off screen.
The NHFA/CSANZ guidelines also
address AF screening among patients with
implantable electronic devices and those
presenting with embolic strokes of
unknown cause.2 These patients are likely
to be a small minority presenting in
general practice, and device-detected AF
will usually be reported to a cardiologist
or neurologist rather than to the GP.

There are simple ways to screen
for AF in general practice and
new technologies and systems
are being developed
Pulse palpation is the simplest and most
cost effective means of screening for AF
and is a free tool available to all GPs.
Research shows that when GPs perform
pulse palpation, their sensitivity for detecting AF is excellent and similar to that of
electronic medical-grade devices.19 Despite
the ease of undertaking pulse palpation,
an international study found only 11% of
Australian GPs performed it regularly.20
The most commonly reported barrier to
pulse palpation is a lack of time during
consultations, with GPs reporting an
already jam-packed consultation agenda,
driven by increasingly complex patients
with multiple comorbidities.21 The high
uptake of electronic blood pressure
monitors that do not report on pulse regularity in general practices may also have
steered practitioners away from pulse
palpation.20
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Both the RACGP and NHFA/CSANZ
guidelines recommend manual pulse
palpation for AF screening; however, the
latter guidelines suggest that devices
producing a medical-quality ECG trace
are preferable, as an ECG is required to
confirm the diagnosis.2,9 Several handheld
single-channel ECG devices with automated rhythm-analysis algorithms for the
detection of AF have been approved by
the TGA and are suitable for opportunistic
single-time point screening. They include
the KardiaMobile (AliveCor) and WIWE
(WIWE Australia).22,23 Both devices are
about the size of a credit card. Patients
place their fingers onto sensors on the
device while a one-lead ECG is recorded
and transmitted to a smart phone or
tablet, where it is analysed by an app with
high sensitivity and specificity for detecting AF (Figure).
Trials of implementing an automated
prompt for GPs to screen for AF incorpor
ated in general practice software coupled
with a handheld ECG device have shown
AF screening to increase to 16%.18 Further
gains in screening prevalence to around
39% have been achieved when screening
is implemented during influenza vaccination clinics, which have high uptake
with the target age group.24 Although this

MED119_Discover_4567_TPC_AW_OL.indd 4

is a substantial gain in screening, it still
falls far short of the screening prevalence
required to substantially reduce AF-
related strokes in Australia. Time constraints in the consultation time are still
reported as the main barrier to achieving
a greater uptake of screening and must be
overcome to increase the effectiveness of
screening.21

Australia is at the forefront of
developing novel approaches to
AF screening in general practice
An AF screening think tank comprising
GPs, cardiologists, GP practice managers,
GP practice nurses and patients was
convened by the Heart Research Institute
in Sydney in 2018 to discuss novel
approaches to increase GP-led AF screening.
The consensus was that higher screening
rates could be achieved if screening was a
minimal burden for practitioners and
reception staff and if the results could be
integrated into the existing workflow of
GPs. A patient self-screening kiosk that
transfers screening results to the patient
medical record and integrates into GP
workflow was raised as an option. We are
currently undertaking a proof-of-concept
study to assess the viability of such an AF
self- screening station in GP practices to

Figure. Example of a TGA-approved handheld
ECG device for detecting atrial fibrillation (AF).
The device is about the size of a credit card
and compatible with most iOS and Android
devices. Patients place their fingers on the
transducer pads for 30 seconds while a
one-lead ECG is recorded and transmitted to
a smart phone or tablet, where it is analysed
by an app with high sensitivity and specificity
for detecting AF. The app provides an
immediate provisional diagnosis of ‘normal’,
‘possible AF’ or ‘unclassified’. ‘Possible AF’
should be verified by GP inspection of the
rhythm strip, followed by a 12-lead ECG.
Image courtesy of AliveCor.

circumvent time pressure in consultations
and better utilise the time patients spend
waiting before a GP appointment for
opportunistic screening.
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Atrial fibrillation screening continued

In all patients aged 65 years and over:
• Perform pulse palpation or check
heart rhythm with a stethoscope
during blood pressure measurement
or chest auscultation
• Use a handheld ECG device to record
a 30 second rhythm strip
• Combine atrial fibrillation (AF)
screening with influenza vaccination
clinics
• Include AF screening in all chronic
health care plans
• Perform AF screening in all heart
health checks
• Include AF screening in all 75 years
and over health checks

Other suggested strategies to help
GPs begin implement opportunistic
screening in their day-to-day practice are
summarised in Box 3. Adopting a routine
moment or opportunity for screening
regularly incorporated into patient care
will detect more disease than ad hoc
screening. New screening technologies
will be effective only if they are routinely
incorporated in practice.

Screening is only one step in
reducing avoidable strokes
Identifying patients with asymptomatic
AF is an important first step in reducing
avoidable stroke, but medical management of high-risk patients needs to be
optimised in tandem with improved
screening to maximise reductions in
avoidable AF-related strokes. The 2018
NHFA/CSANZ guidelines provide
guidance on evidence-based management of newly diagnosed and existing
AF, as summarised in the November 2019
issue of Medicine Today.25 Important
changes are the omission of antiplatelet
agents as medications to reduce stroke
risk when AF is diagnosed, and the
recognition that the benefits of stroke
and mortality reduction from oral
20 MedicineToday

anticoagulant therapy outweigh the risk
of major haemorrhage in patients at
increased stroke risk (CHA2DS2-VA score
of 2 or more).
Reassuring data suggest that the
management of AF has improved in
Australia over the past decade, with prescription rates of oral anticoagulants
among 
h igh-risk patients steadily
increasing.26 Although this is promising,
there is scope for further improvement,
as between one-third and one-quarter
of patients with AF and high risk of
stroke are not taking oral anticoagulant
therapy.17 In countries where oral anticoagulant prescription rates have
increased substantially, the AF-related
stroke rate has decreased substantially.27,28
In the UK, oral anticoagulant prescription rates increased from 48.0% to 78.6%
between 2006 and 2016, and this was
estimated to have prevented 4068 strokes
in 2015-2016 alone.10,27
Optimising patient adherence and
persistence in taking oral anticoagulants
is another challenge for GPs to reduce
the incidence of avoidable strokes, as
adherence to oral anticoagulants drops
to less than 50% by 12 months after their
initial prescription.2,26 Consequently,
improved screening rates need to be
combined with better management of
high-risk patients and focused strategies
to improve adherence and persistence
with oral anticoagulant therapy to reduce
avoidable strokes.

Conclusion
GPs are optimally positioned to reduce
AF-related strokes, and screening for
silent AF is a simple and cost effective
way to identify patients who are at high
risk of stroke. New Australian guidelines
recommend opportunistic screening
among patients aged 65 years and older,
and there are multiple ways GPs can
incorporate this into their day-to-day
practice, as well as new technologies
that may circumvent the time barriers
faced by practitioners. A multipronged
approach that improves screening rates,

COVID-19 AND GP SCREENING
FOR ATRIAL FIBRILLATION
• The rapid uptake of telehealth
consultations by GPs in response
to the COVID-19 pandemic has
introduced further challenges for
GPs to undertake opportunistic
screening for atrial fibrillation (AF).
• Achieving higher AF screening rates
among patients attending face-toface consultations has become
even more salient in this context, to
reduce the incidence of AF-related
strokes.

oral anticoagulant prescription and
adherence among high-risk patients will
result in the greatest reductions in AF-
related strokes.  MT

References
A list of references is included in the online version of
this article (www.medicinetoday.com.au).

COMPETING INTERESTS: Dr Giskes has received
honoraria from Pfizer and is supported by a grant
from the RACGP/HCF Foundation Grant (reference
number HCF 23). Associate Professor Hespe has
received honoraria from Pfizer. Professor
Freedman has received grants, personal fees and
nonfinancial support from Bayer, BMS-Pfizer,
Daiichi Sankyo, AliveCor and Omron.

ONLINE CPD JOURNAL PROGRAM
Australian guidelines recommend
opportunistic screening for atrial
fibrillation from what patient age?

Review your knowledge of this topic
and earn CPD points by taking part
in MedicineToday’s Online CPD Journal
Program. Log in to

www.medicinetoday.com.au/cpd

❙ JUNE 2020, VOLUME 21, NUMBER 6
Downloaded for personal use only. No other uses permitted without permission. © MedicineToday 2020.

© WILDPIXEL/ISTOCKPHOTO.COM

3. WHAT CAN GPS DO IN THEIR
PRACTICES TO IMPLEMENT AN
ATRIAL FIBRILLATION SCREENING
PROGRAM?

MedicineToday 2020; 21(6): 14-20

Screening for atrial
fibrillation
The essential role of GPs
KATRINA GISKES

MB BS, PhD, BHSc(Nut&Diet)(Hons);

BEN FREEDMAN

CHARLOTTE HESPE

MB BS(Hons), FRACGP, DCH, GCUT

MB BS, PhD, FRACP, FCSANZ, FAHA, FACC, FESC

References
1. Diouf I, Magliano DJ, Carrington MJ, Stewart S, Shaw JE. Prevalence,

practice: the GP-SEARCH qualitative pilot study. Aust Fam Physician 2014; 43:

incidence, risk factors and treatment of atrial fibrillation in Australia: The

315-319.

Australian Diabetes, Obesity and Lifestyle (AusDiab) longitudinal, population

16. Lowres N, Olivier J, Chao TF, et al. Estimated stroke risk, yield, and number

cohort study. Int J Cardiol 2016; 205: 127-132.

needed to screen for atrial fibrillation detected through single time screening: a

2. Brieger D, Amerena J, Attia JR, et al. National Heart Foundation of Australia

multicountry patient-level meta-analysis of 141,220 screened individuals.

and Cardiac Society of Australia and New Zealand: Australian clinical guidelines

PLoS Med 2019; 16: e1002903.

for the diagnosis and management of atrial fibrillation 2018. Med J Aust 2018;

17. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of

209: 356-62.

stroke prevention through community screening for atrial fibrillation using

3. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial

iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014;

fibrillation: an increasing epidemic and public health challenge. Int J Stroke

111: 1167-1176.

2020: 1747493019897870.

18. Orchard J, Neubeck L, Freedman B, et al. eHealth tools to provide structured

4. Freedman B, Camm J, Calkins H, et al. Screening for atrial fibrillation: a

assistance for atrial fibrillation screening, management, and guideline-

report of the AF-SCREEN International Collaboration. Circulation 2017;

recommended therapy in metropolitan general practice: The AF-SMART Study.

135: 1851-1867.

J Am Heart Assoc 2019; 8: e010959.

5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to

19. Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of methods

prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern

for detecting an irregular pulse and suspected atrial fibrillation: a systematic

Med 2007; 146: 857-867.

review and meta-analysis. Eur J Prev Cardiol 2016; 23: 1330-1338.

6. Royal Australian College of General Practitioners. Guidelines for preventive

20. The Economist Intelligence Unit. Preventing stroke: uneven progress. A

activities in general practice. 9th ed. Melbourne: RACGP; 2016.

global policy research program. The Economist Intelligence Unit; 2017.

7. Dennis S. From organisations to people: improving the prevention and

21. Orchard J, Li J, Gallagher R, Freedman B, Lowres N, Neubeck L. Uptake of a

management of long-term conditions in Australian primary health care. Aust J

primary care atrial fibrillation screening program (AF-SMART): a realist evaluation

Prim Health 2017; 23(5): i-ii.

of implementation in metropolitan and rural general practice. BMC Fam Pract

8. World Health Organization. Screening programmes: a short guide. Increase

2019; 20: 170.

effectiveness, maximize benefits and minimize harm. Copenhagen: WHO

22. AliveCor. KardiaMobile. Available online at: www.alivecor.com/kardiamobile

Regional Office for Europe; 2020.

(accessed May 2020).

9. Royal Australian College of General Practitioners. General practice: health

23. MyWIWE. What is a WIWE. Available online at: https://mywiwe.com.au/

of the nation 2018. Melbourne: RACGP; 2018.

what-is-a-wiwe (accessed May 2020).

10. Freedman B. Major progress in anticoagulant uptake for atrial fibrillation at

24. Orchard J, Lowres N, Freedman SB, et al. Screening for atrial fibrillation

last: does it translate into stroke prevention? Eur Heart J 2018; 39: 2984-2986.

during influenza vaccinations by primary care nurses using a smartphone

11. Friberg L, Rosenqvist M, Lindgren A, Terent A, Norrving B, Asplund K. High

electrocardiograph (iECG): a feasibility study. Eur J Prev Cardiol 2016; 23(2

prevalence of atrial fibrillation among patients with ischemic stroke. Stroke

Suppl): 13-20.

2014; 45: 2599-2605.

25. Brieger D, Connell C, Hespe C, Zwar N. Atrial fibrillation management: the

12. Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic

central role of the GP. Med Today 2019; 20(11): 10-16.

atrial fibrillation: a systematic review of age/gender differences and

26. Lowres N, Giskes K, Hespe C, Freedman B. Reducing stroke risk in atrial

cardiovascular outcomes. Int J Cardiol 2015; 191: 172-177.

fibrillation: adherence to guidelines has improved, but patient persistence with

13. Freedman SB, Lowres N. Asymptomatic atrial fibrillation: the case for

anticoagulant therapy remains suboptimal. Korean Circ J 2019; 49: 883-907.

screening to prevent stroke. JAMA 2015; 314: 1911-1912.

27. Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of

14. Neubeck L, Orchard J, Lowres N, Freedman SB. To screen or not to screen?

hospitalized atrial fibrillation-related stroke in England and its association with

Examining the arguments against screening for atrial fibrillation. Heart Lung

uptake of oral anticoagulation. Eur Heart J 2018; 39: 2975-2983.

Circ 2017; 26: 880-886.

28. Chao TF, Chiang CE, Lin YJ, et al. Evolving changes of the use of oral

15. Orchard J, Freedman SB, Lowres N, Peiris D, Neubeck L. iPhone ECG

anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation

screening by practice nurses and receptionists for atrial fibrillation in general

in Taiwan. Circulation 2018; 138: 1485-1487.

Downloaded for personal use only. No other uses permitted without permission. © MedicineToday 2020.

